EOC is a heterogeneous category comprising several histologic subtypes that differ in risk factors and behavior. Although the development of EOC is likely to be a complex and multifactorial process, ...
An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma. Safety and efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results